Admin Posted February 26, 2019 Share Posted February 26, 2019 Some of our members are participating in the third Australian Lutetium-177 trial. In this current trial, Lutetium-177 is being compared with the best current treatment - Cabazitaxel (Jevtana). Lutetium-177 is also known as Lu-177 or 177Lu or Lutetium-177 PSMA-617. We earlier reported on the results of the first Australian Lutetium-177 trial: Now UroToday has reported the results of the second trial here: https://t.co/LpQf8G0hdT OR https://www.urotoday.com/conference-highlights/asco-gu-2019/asco-gu-2019-prostate-cancer/110311-asco-gu-2019-results-of-a-50-patient-single-centre-phase-ii-prospective-trial-of-lutetium-177-psma-617-theranostics-in-mcrpc.html?utm_source=newsletter_6299&utm_medium=email&utm_campaign=emerging-data-in-the-treatment-of-men-with-mcrpc If you are further interested, Michael Hofman, who led the study from the Peter MacCallum Centre in Melbourne, Australia is interviewed here: https://www.urotoday.com/video-lectures/asco-gu-2019/video/mediaitem/1155-embedded-media2019-02-23-19-51-36.html The first time you go to UroToday you will need to sign up, but signing up is free. If these links do not work for you, on the UroToday.com site, search for: hofman Thanks to member Chuck for the referral to this report. Jim Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.